This is from our sibling paper, the Boston Business Journal:
Sanofi-Aventis CEO Chris Viehbacher outlined the research and development strategy that led to the purchase of Cambridge, Mass-based Genzyme Corp. for $20.1 billion, and will lead the company to further expand its partnerships and acquisitions.
“My goal as CEO is never to inaugurate a new research and development center,” Viehbacher said during an MIT Enterprise Forum event, at the start of his first full week as CEO of Genzyme, now a Sanofi subsidiary.
No comments:
Post a Comment